Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
476 stopped studies mapped to Malignant Ovarian Neoplasm and descendants · 86% state a reason
Over the 476 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01521143 | Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete…(CANVAS) | Phase 2 | terminated | Jan 30, 2012 | Prima BioMed Ltd | The study was terminated due to company restructuring and changes in drug development priorities. | Sponsor / business decision |
| NCT02035345 | Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment | Phase 4 | terminated | Jan 14, 2014 | Massachusetts General Hospital | Extended Carboplatin Infusion did not Reduce Frequency of Hypersensitivity Reactions | Other (stated, no rule matched) |
| NCT00637390 | A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal… | Phase 1 | terminated | Mar 18, 2008 | University of Michigan Rogel Cancer Center | Genzyme will no longer supply the study drug for this trial as it does not believe the study will… | Drug supply |
| NCT00842582 | Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer | Phase 1 | withdrawn | Feb 12, 2009 | Loyola University | No enrollment. Unable to recruit due to lack of eligible patients. | Enrollment / accrual |
| NCT01227941 | MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced… | Phase 1 | terminated | Oct 25, 2010 | Tesaro, Inc. | not stated | Not stated |
| NCT02667925 | Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal…(ISOTOVE) | N/A | withdrawn | Jan 29, 2016 | Centre Jean Perrin | Because of the obsolescence of the study | Other (stated, no rule matched) |
| NCT00862836 | Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)(ZACFAST) | Phase 1 / Phase 2 | terminated | Mar 17, 2009 | Genzyme, a Sanofi Company | Lack of efficacy | Efficacy / futility |
| NCT02469116 | Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With… | Phase 2 | terminated | Jun 11, 2015 | Washington University School of Medicine | Sponsor withdrew financial support | Funding |
| NCT02083536 | LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma | Phase 1 | withdrawn | Mar 11, 2014 | University of Miami | Study voluntarily stopped by Principal Investigator due to lack of accrual. | Investigator |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced… | Phase 1 | withdrawn | Dec 11, 2015 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT01003938 | Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer | Phase 2 | terminated | Oct 29, 2009 | NYU Langone Health | due to administrative issue and financial sponsor decision to suspend ovarian cancer studies | Funding |
| NCT00003852 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients… | Phase 2 | terminated | Jan 27, 2004 | UNICANCER | lack of patient inclusion | Other (stated, no rule matched) |
| NCT00634894 | Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary… | Phase 2 | withdrawn | Mar 13, 2008 | M.D. Anderson Cancer Center | Study halted with no registration, the drug company sponsor withdrew support. | Sponsor / business decision |
| NCT00526799 | Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer | Phase 1 / Phase 2 | terminated | Sep 10, 2007 | Daniela Matei, MD | Study closed to accrual due unfavorable interim analysis | Efficacy / futility |
| NCT00522301 | Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or… | Phase 2 | terminated | Aug 29, 2007 | Memorial Sloan Kettering Cancer Center | not stated | Not stated |
| NCT02470559 | Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients… | Phase 1 | withdrawn | Jun 12, 2015 | Barbara Ann Karmanos Cancer Institute | Study did not accrue any participants, the PI has left the institution. | Enrollment / accrual |
| NCT01624493 | BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients | Phase 1 / Phase 2 | withdrawn | Jun 20, 2012 | Hoosier Cancer Research Network | Phase I was conducted Australia. Phase II not conducted and no US pts enrolled. | Enrollment / accrual |
| NCT01840943 | A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial… | Phase 3 | terminated | Apr 26, 2013 | Xian-Janssen Pharmaceutical Ltd. | the study was terminated due to medication supply issue from current manufacturer | Drug supply |
| NCT00313612 | Oxaliplatin and Topotecan in Advance Ovarian Cancer | Phase 2 | terminated | Apr 12, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00596544 | Sexual Functioning After Primary Treatment of Ovarian Cancer | — | terminated | Jan 17, 2008 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With… | Phase 1 / Phase 2 | terminated | Jan 23, 2014 | Otsuka Novel Products GmbH | not stated | Not stated |
| NCT01175967 | Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced… | — | terminated | Aug 5, 2010 | UNC Lineberger Comprehensive Cancer Center | Unable to meet accrual due to changing practice patters | Enrollment / accrual |
| NCT00093678 | Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer | N/A | withdrawn | Oct 8, 2004 | Eastern Cooperative Oncology Group | not stated | Not stated |
| NCT00758732 | Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian… | Phase 2 | terminated | Sep 25, 2008 | Hellenic Oncology Research Group | Poor accrual | Enrollment / accrual |
| NCT01296035 | Panitumumab and Gemcitabine in Relapsed Ovarian Cancer(PanGem) | Phase 2 | terminated | Feb 15, 2011 | Women and Infants Hospital of Rhode Island | Newer technologies available; poor accrual to study. | Enrollment / accrual |
| NCT01744821 | Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary… | N/A | terminated | Dec 7, 2012 | Northwestern University | Inability to recruit study subjects | Enrollment / accrual |
| NCT01175772 | Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment… | Phase 2 | terminated | Aug 5, 2010 | HaEmek Medical Center, Israel | Due to change in the national policy of medications | Other (stated, no rule matched) |
| NCT00323726 | Trends in Incidence and Survivals for Ovarian Germ Cell Tumors: A 27-Year… | — | withdrawn | May 9, 2006 | New Mexico Cancer Research Alliance | The study was limited to IRB Exempt chart review; not an applicable trial. | Other (stated, no rule matched) |
| NCT01880996 | Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies | Phase 1 / Phase 2 | withdrawn | Jun 19, 2013 | Sheba Medical Center | The deparment failed to detect patients that were willing to participate in this study | Other (stated, no rule matched) |
| NCT00053235 | Research Study in Patients With Advanced Ovarian Epithelial Cancer | — | withdrawn | Jan 28, 2003 | Gynecologic Oncology Group | not stated | Not stated |
| NCT01200797 | SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian… | Phase 2 | terminated | Sep 14, 2010 | National Cancer Institute (NCI) | Slow accrual was the reason for study termination. | Enrollment / accrual |
| NCT00003880 | Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly… | Phase 2 / Phase 3 | terminated | Apr 23, 2004 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00659399 | Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian… | Phase 1 | withdrawn | Apr 16, 2008 | NYU Langone Health | Low accrual | Enrollment / accrual |
| NCT01017809 | Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated… | N/A | withdrawn | Nov 23, 2009 | NYU Langone Health | NYU 03-67 reached accrual prior to this study opening. | Enrollment / accrual |
| NCT00442598 | Safety and Efficacy Study of Glufosfamide in Ovarian Cancer | Phase 2 | terminated | Mar 2, 2007 | Eleison Pharmaceuticals LLC. | not stated | Not stated |
| NCT00023634 | S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer | Phase 1 | terminated | Jan 27, 2003 | SWOG Cancer Research Network | lack of accrual | Enrollment / accrual |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel… | Phase 1 / Phase 2 | terminated | Oct 5, 2007 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00312650 | Doxil and Gemcitabine in Recurrent Ovarian Cancer | Phase 2 | terminated | Apr 10, 2006 | Women and Infants Hospital of Rhode Island | not stated | Not stated |
| NCT01492920 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With… | Phase 3 | withdrawn | Dec 15, 2011 | Gynecologic Oncology Group | Withdrawn | Other (stated, no rule matched) |
| NCT01927393 | Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV… | N/A | withdrawn | Aug 22, 2013 | City of Hope Medical Center | Study was not funded | Funding |
| NCT01747239 | Cabazitaxel in Platinum Refractory Ovarian Cancer | Phase 2 | terminated | Dec 11, 2012 | Vejle Hospital | Too low inclusion rate. Only 4 patients included over 16 months | Other (stated, no rule matched) |
| NCT00787488 | Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca | N/A | withdrawn | Nov 7, 2008 | Mark Dewhirst | Study not funded | Funding |
| NCT01149434 | Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or… | Phase 1 / Phase 2 | terminated | Jun 23, 2010 | University of Utah | Lack of drug efficacy | Efficacy / futility |
| NCT01095367 | Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of… | N/A | terminated | Mar 30, 2010 | University of British Columbia | due to company changes and lack of funding-unlikely to have sufficient numbers to analyze… | Funding |
| NCT02017678 | Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer… | Phase 2 | withdrawn | Dec 23, 2013 | Andrea McCart | not stated | Not stated |
| NCT00536523 | Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With… | — | terminated | Sep 28, 2007 | University of Minnesota | Funding unavailable | Funding |
| NCT01284075 | The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After… | N/A | terminated | Jan 26, 2011 | University of Minnesota | Low accrual | Enrollment / accrual |
| NCT01606358 | Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian…(IClyCO) | — | withdrawn | May 25, 2012 | Rennes University Hospital | not stated | Not stated |
| NCT00418093 | Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma | Phase 2 | terminated | Jan 4, 2007 | Dana-Farber Cancer Institute | THe study was terminated early due to a lack of accural | Other (stated, no rule matched) |
| NCT01233505 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 3, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 14, 2016source: clinicaltrials